After Intepirdine Flunked in Alzheimer’s Disease, Is Axovant Sciences a Buy?
Hope was running high at Axovant Sciences (NASDAQ: AXON) that that teaming up their drug intepirdine with the top-selling Alzheimer's disease treatment, Aricept, could improve patients' lives. Unfortunately, intepirdine failed to outperform a placebo in its study, a result that casts doubt over Axovant Sciences' future.
In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Michael Douglass and contributor Todd Campbell unpack this news and offer up their take on why Axovant shares are still risky, even after the 70% drop the took following the disappointing clinical trial news.
A full transcript follows the video.
Source: Fool.com
Biogen Inc. Stock
€194.45
-7.430%
With 51 Buy predictions and 1 Sell predictions Biogen Inc. is one of the favorites of our community.
As a result the target price of 291 € shows a positive potential of 49.65% compared to the current price of 194.45 € for Biogen Inc..
